Edition:
United Kingdom

argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

73.30EUR
4:35pm BST
Change (% chg)

€-0.20 (-0.27%)
Prev Close
€73.50
Open
€73.10
Day's High
€73.50
Day's Low
€71.10
Volume
78,725
Avg. Vol
97,018
52-wk High
€94.80
52-wk Low
€18.90

Chart for

About

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused... (more)

Overall

Beta: --
Market Cap(Mil.): €583.54
Shares Outstanding(Mil.): 26.89
Dividend: --
Yield (%): --

Financials

  ARGX.BR Industry Sector
P/E (TTM): -- 85.68 33.65
EPS (TTM): -1.07 -- --
ROI: -19.69 0.45 14.28
ROE: -19.69 1.37 16.00

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

22 Aug 2018

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).

22 Aug 2018

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS, Aug 22 Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million.

22 Aug 2018

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS

25 Jul 2018

BRIEF-Argenx Q1 Operating Income Down At 6.9 Million Euros

* ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

09 May 2018

BRIEF-Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)

* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING

24 Apr 2018

Earnings vs. Estimates